Parkinsonism in cirrhosis: pathogenesis and current therapeutic options

[1]  R. Butterworth.  Liver: Risk of falls in cirrhosis predicted by psychometric testing , 2012, Nature Reviews Gastroenterology &Hepatology.

[2]  K. Weissenborn.  Parkinsonism in patients with cirrhosis: coincidence or consequence? , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[3]  A. Stracciari,et al.  Chronic acquired hepatocerebral degeneration: effects of liver transplantation on neurological manifestations , 2011, Neurological Sciences.

[4]  F. Grandas,et al.  Acquired hepatocerebral degeneration: clinical characteristics and MRI findings , 2010, European journal of neurology.

[5]  K. Demır,et al.  Are Acquired Hepatocerebral Degeneration and Hepatic Myelopathy Reversible? , 2009, Journal of clinical gastroenterology.

[6]  C. Choi,et al.  Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration , 2008, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Butterworth.  Neuronal cell death in hepatic encephalopathy , 2007, Metabolic Brain Disease.

[8]  Antonio P Strafella,et al.  Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. , 2007, Archives of neurology.

[9]  E. Schiff,et al.  Acquired hepatocerebral degeneration in a patient with HCV cirrhosis: Complete resolution with subsequent recurrence after liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  C. Cowl,et al.  Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. , 2005, Archives of neurology.

[11]  R. D. Du Pasquier,et al.  Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. , 2003, Archives of neurology.

[12]  D. Hochstrasser,et al.  Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  G. P. Layrargues.  Movement Dysfunction and Hepatic Encephalopathy , 2001, Metabolic Brain Disease.

[14]  H. Köstler,et al.  Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy , 2000, Metabolic Brain Disease.

[15]  F. Lazeyras,et al.  Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. , 2000, Gastroenterology.

[16]  R. Butterworth,et al.  Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. , 1999, Gastroenterology.

[17]  R. Butterworth,et al.  Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end‐stage liver disease , 1997, Hepatology.

[18]  R. Butterworth,et al.  Distinctive pattern of Bergmann glial pathology in human hepatic encephalopathy. , 1997, Molecular and chemical neuropathology.

[19]  B. Snow,et al.  Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication , 1997, Neurology.

[20]  R. Butterworth,et al.  Increased Density of Catalytic Sites and Expression of Brain Monoamine Oxidase A in Humans with Hepatic Encephalopathy , 1997, Journal of neurochemistry.

[21]  R. Butterworth,et al.  Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms , 1996, Hepatology.

[22]  R. Butterworth,et al.  Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy , 1995, Metabolic Brain Disease.

[23]  R. Butterworth,et al.  Accumulation of manganese and copper in pallidum of cirrhotic patients: role in the pathogenesis of hepatic encephalopathy? , 1995, Metabolic Brain Disease.

[24]  R. Butterworth,et al.  Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy , 1993, Neuroscience Letters.

[25]  R. Butterworth,et al.  Increased activities of MAOA and MAOB in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy , 1993, Brain Research.

[26]  S. Mirowitz,et al.  Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. , 1991, Radiology.

[27]  S. Hori,et al.  Portal-systemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images. , 1991, Radiology.

[28]  J. Chalk,et al.  Improvement in chronic hepatocerebral degeneration following liver transplantation. , 1990, Gastroenterology.

[29]  R. Butterworth,et al.  Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy , 1989, Neurochemical Research.

[30]  M H Finlayson,et al.  Distribution of cerebral lesions in acquired hepatocerebral degeneration. , 1981, Brain : a journal of neurology.

[31]  F. Pons,et al.  Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial. , 1980, Gastroenterology.

[32]  M. Uribe,et al.  Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial. , 1979, Gastroenterology.

[33]  C. O. Kennedy.  A controlled trial , 1971, British Homeopathic Journal.

[34]  J. Stern,et al.  Hepatic cirrhosis with post-shunt myelopathy. , 1970, Journal of the neurological sciences.

[35]  W. Meissner,et al.  Acquired hepatocerebral degeneration. , 2011, Handbook of clinical neurology.

[36]  James,et al.  Treatment of chronic hepatic encephalopathy with levodopa' , 2006 .

[37]  S. Sherlock,et al.  Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. , 1980, Gastroenterology.

[38]  S Fahn,et al.  Chronic manganese intoxication. , 1974, Archives of neurology.